News & Events
SAN DIEGO, May 31, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming investor conferences. Dr. Lian will present at the 7th Annual LD Micro Invitational, being held June 6-7, 2017 in Los Angeles and the 2017 Marcum Microcap Conference, being held June 15-16, 2017 in New York City.
Details of these presentations are as follows:
- 7th Annual LD Micro Invitational
Time/Date: 8:30 a.m. PT on Tuesday, June 6, 2017
Location: Luxe Sunset Boulevard Hotel, Los Angeles
Room: Track 1
- 2017 Marcum Microcap Conference
Time/Date: 3:00 p.m. ET on Thursday, June 15, 2017
Location: Grand Hyatt Hotel, New York
Room: Broadway – Conference Level
To access live webcasts of Viking's presentations, when available, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, replays of webcasts will be available on the Viking website.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
SOURCE Viking Therapeutics, Inc.